The present study demonstrated that a heterologous second booster dose of BNT162b2, administered following a primary two-dose CoronaVac regimen for COVID-19 vaccination, rapidly induced CD4+ T and B cell responses that were maintained for at least 6 months. Here, CD4 is linked to COVID-19.